South Korean senior citizens receive their first dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a vaccination centre in Seoul, South Korea April 1, 2021. Chung Sung-Jun/Pool via REUTERS
SEOUL, July 5 (Reuters) – South Korea is in talks with mRNA vaccine makers including Pfizer (PFE.N) and Moderna (MRNA.O) to produce COVID-19 shots in the country and is ready to offer the capacity to make up to 1 billion doses immediately, a senior government official said.
The plan, if agreed, would help ease tight global supply of COVID-19 vaccines, particularly in Asia which lags North America and Europe in vaccine rollouts, and put South Korea a step closer to its ambition to become a major vaccine manufacturing centre.
South Korea already has deals to locally produce three coronavirus vaccines developed by AstraZeneca (AZN.L)/Oxford University, Novavax (NVAX.O), and Russia. It also has a vaccine bottling and packaging deal with Moderna.
“We’ve been holding frequent talks with big pharmaceutical companies to produce mRNA vaccines,” Lee Kang-ho, director general for the global vaccine hub committee under South Korea’s health ministry, told Reuters in an interview.
“There are only a few mRNA vaccine developers – Pfizer, Moderna, CureVac and BioNTech. Thus there’s a limit to how much they can produce to meet global demand… South Korea is keen to help by offering its facilities and skilled human resources,” Lee said.
It’s not immediately clear how advanced these talks are and whether and when a deal will be agreed.
BioNTech (22UAy.DE) declined to comment, Moderna and CureVac (5CV.DE) did not reply to Reuters’ requests for comments.
A Pfizer spokesperson said the company is making efforts to enhance its COVID-19 vaccine supply chain but added “we do not have anything specific to announce at this time.”
Lee declined to name local vaccine makers which have the capacity to produce mRNA vaccines immediately, but a government source said they include Hanmi Pharmaceuticals Co Ltd (128940.KS) and Quratis Co Ltd.
Hanmi confirmed that it has a big capacity reserved for Sanofi’s (SASY.PA) diabetes drug and it can be used for COVID-19 vaccine production as the Sanofi project has stalled.
“We happen to have this facility available right now because our clinical trial (with Sanofi) was discontinued in the middle of last year,” Kim Soo-jin, senior vice president of Hanmi, told Reuters.
“It’s very timely that we have a fully ready, GMP, state-of-the-art facility available,” she said, referring to good manufacturing practice.
Quratis, which makes a tuberculosis vaccine, said its new factory built last year can now be used for mRNA vaccine production.
Shares in Hanmi erased early losses and rose nearly 4% on Monday after the Reuters report.
COLLABORATION WITH WHO
South Korea has stepped up its effort to produce more vaccines since U.S. President Joe Biden in May agreed with South Korean President Moon Jae-in on a comprehensive partnership on COVID-19 vaccines. read more
Lee said his team is having frequent video conference calls with the vaccine makers and the World Health Organization (WHO).
WHO spokesman Tarik Jasarevic told Reuters the organisation is “talking with South Korea and other countries,” but did not elaborate.
The WHO said last month it will set up a hub in South Africa to manufacture mRNA vaccines within 9-12 months that will give companies from poor and middle-income countries the know-how and licenses to produce COVID-19 vaccines. read more
Lee said mRNA vaccine makers may be reluctant to share their technology, but they can take advantage of South Korea’s raw material suppliers to address a global shortage of such ingredients as lipids, nucleotides and capping reagents.
“They’re capable of manufacturing and developing such raw materials to help vaccine makers… and the South Korean government is committed to provide all necessary support including financial and administrative aid.”
Lee said the country also has a capacity for at least another 500 million doses of fill-and-finish vaccines apart from the deal Moderna announced with Samsung BioLogics (207940.KS) in May.
Reporting by Sangmi Cha in Seoul; Additional reporting by Stephanie Nebehay in Geneva, Michael Erman in New York and Ludwig Burger in Frankfurt; Editing by Miyoung Kim and Raju Gopalakrishnan
Our Standards: The Thomson Reuters Trust Principles.